Addyi to the rescue of VRX, couldn't come at a better timethere is no limit to sales as opposed to regular drugs which are limited by the number of patients, any pre-menopausal woman could buy it, we're talking tens of millions in the US alone
As part of its deal last year to buy Sprout Pharmaceuticals and the Addyi drug, Valeant committed to spend $200 million on sales and other expenses through June 2017 (see page 13). And even though the company voluntarily agreed last summer to refrain from consumer advertising for 18 months, this means that women could start seeing ads early next year.
“This is a risky drug about which women and their doctors don’t get enough information,” said Cindy Pearson, who heads the National Women’s Health Network, which released the report card. “It’s true that not many women are using the drug now, but once advertising starts, we can expect more women to see the messaging and become interested in the product. And that means more women are likely to be exposed to the risks.”
In fact, the company was given a “D” for provider education.